Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) was upgraded by research analysts at Cantor Fitzgerald from a “neutral” rating to an “overweight” rating in a research report issued on Tuesday, MarketBeat Ratings reports. The firm currently has a $12.00 price objective on the software maker’s stock. Cantor Fitzgerald’s price target suggests a potential downside of 6.61% from the company’s previous close.

Other equities analysts have also issued research reports about the company. Bank of America Corporation began coverage on Allscripts Healthcare Solutions in a research note on Monday, May 15th. They issued a “neutral” rating and a $14.00 target price for the company. Citigroup Inc. raised their target price on Allscripts Healthcare Solutions from $13.00 to $14.00 and gave the stock a “neutral” rating in a research note on Monday, August 7th. BidaskClub upgraded Allscripts Healthcare Solutions from a “sell” rating to a “hold” rating in a research note on Saturday, June 24th. Leerink Swann lowered Allscripts Healthcare Solutions from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $15.00 to $13.00 in a research note on Monday, June 19th. Finally, Zacks Investment Research upgraded Allscripts Healthcare Solutions from a “sell” rating to a “hold” rating in a research note on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and ten have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $14.59.

Shares of Allscripts Healthcare Solutions (MDRX) traded up 0.94% on Tuesday, reaching $12.85. The company’s stock had a trading volume of 3,035,295 shares. The firm’s market capitalization is $2.32 billion. Allscripts Healthcare Solutions has a one year low of $9.80 and a one year high of $13.70. The firm has a 50-day moving average price of $12.50 and a 200 day moving average price of $12.18.

Allscripts Healthcare Solutions (NASDAQ:MDRX) last issued its earnings results on Thursday, August 3rd. The software maker reported $0.11 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.15 by $0.04. The firm had revenue of $426.10 million during the quarter, compared to analysts’ expectations of $424.94 million. Allscripts Healthcare Solutions had a positive return on equity of 5.97% and a negative net margin of 11.54%. The business’s revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the business earned $0.14 EPS. On average, analysts anticipate that Allscripts Healthcare Solutions will post $0.62 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was first reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/08/15/allscripts-healthcare-solutions-inc-mdrx-upgraded-at-cantor-fitzgerald.html.

Several institutional investors have recently made changes to their positions in the stock. FNY Partners Fund LP raised its position in shares of Allscripts Healthcare Solutions by 900.0% in the first quarter. FNY Partners Fund LP now owns 8,000 shares of the software maker’s stock valued at $101,000 after buying an additional 7,200 shares in the last quarter. Invictus RG acquired a new position in shares of Allscripts Healthcare Solutions during the first quarter valued at $105,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Allscripts Healthcare Solutions by 9.5% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,434 shares of the software maker’s stock valued at $120,000 after buying an additional 816 shares in the last quarter. Bank of Montreal Can raised its position in shares of Allscripts Healthcare Solutions by 60.2% in the first quarter. Bank of Montreal Can now owns 9,914 shares of the software maker’s stock valued at $126,000 after buying an additional 3,724 shares in the last quarter. Finally, Flinton Capital Management LLC raised its position in shares of Allscripts Healthcare Solutions by 4.1% in the first quarter. Flinton Capital Management LLC now owns 9,940 shares of the software maker’s stock valued at $126,000 after buying an additional 392 shares in the last quarter.

Allscripts Healthcare Solutions Company Profile

Allscripts Healthcare Solutions, Inc (Allscripts) delivers information technology (IT) solutions and services to help healthcare organizations. The Company operates through three segments: Clinical and Financial Solutions, Population Health, and Netsmart. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions.

Analyst Recommendations for Allscripts Healthcare Solutions (NASDAQ:MDRX)

Receive News & Ratings for Allscripts Healthcare Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.